

JONAS CENTER

CELLULAR THERAPY SYMPOSIUM

PHYSICIAN CREDIT: The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 6 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER HEALTH PROFESSIONS CREDIT: Other participants will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME, please consult your professional licensing board.

REGISTRATION

Early registration ends August 22, 2025

PHYSICIAN & RESEARCH PROFESSIONALS

In-Person | Early \$140
 | Regular \$175

OTHER HEALTHCARE PROFESSIONAL

In-Person | Early \$95
 | Regular \$120

RESIDENTS & FELLOWS

(With verification letter)

In-Person | Early \$25
 | Regular \$25

UCHICAGO, WASHU & MCW FACULTY & STAFF

In-Person | Early \$25
 | Regular \$25



AT THE FOREFRONT

**UChicago
Medicine**

The University of Chicago
Center for Continuing
Medical Education
5841 S. Maryland Ave., MC 1137
Chicago, IL 60637

Follow us on Twitter:
@UChicagoCME

SCAN TO
REGISTER!



FOR MORE INFORMATION & TO REGISTER:
www.JonasCenterSymposium.com

QUESTIONS? Contact Meeting Achievements:
219.465.1115 or by email at
support@meetingachievements.com

JONAS CENTER

CELLULAR THERAPY SYMPOSIUM

SEPTEMBER 26, 2025

THE DAVID RUBENSTEIN FORUM | CHICAGO, ILLINOIS

VISIT: JonasCenterSymposium.com

CO-HOSTED BY:



David and Etta Jonas
Center for Cellular
Therapy



This conference will highlight basic and translational research advances in the field of cellular therapy for hematologic malignancies, solid tumors, and non-oncologic conditions.

TARGET AUDIENCE: This activity is designed for basic and translational researchers, hematology and medical oncology physicians and fellows, immunologists, and healthcare professionals interested in tumor immunology and cellular immunotherapy.

COURSE DESCRIPTION

Immerse yourself in groundbreaking advancements in adoptive immunotherapy that are revolutionizing the treatment landscape for hematologic malignancies and beyond.

Join us as we convene esteemed national experts in a forum for collaboration and scientific discourse. Together, we'll delve into basic science and translational research, unlocking the potential of cellular therapeutics for hematologic malignancies, solid tumors, and non-oncologic conditions.

COURSE DIRECTORS

Peter Riedell, MD
University of Chicago Medicine

John DiPersio, MD, PhD
WashU Medicine

Nirav N. Shah, MD, MSHTP
Medical College of Wisconsin

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Identify key toxicities of CAR T-cell therapy, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS);
2. Summarize therapeutic applications of cellular and gene therapies in classical hematology;
3. Explain the immunologic and cellular pathways contributing to CAR T-cell-related toxicities;
4. Compare existing cellular therapy strategies and their limitations in treating solid tumors;
5. Discuss logistical and financial challenges impacting cellular and gene therapy access in hematologic diseases;
6. Analyze novel antigen targets and therapeutic constructs for cellular therapy in solid tumor malignancies;
7. Evaluate clinical and biological barriers to implementing CAR T-cell therapy in myeloid malignancies;
8. Assess the translational potential of emerging cellular therapy strategies for hematologic and solid tumor indications.

CONFERENCE LOCATION**IN-PERSON:**

University of Chicago
David Rubenstein Forum,
1201 E. 60th St. Chicago, IL 60637

8:00 am **REGISTRATION, EXHIBITS, & BREAKFAST**

8:30 am **WELCOME & INTRODUCTIONS**
Peter Riedell, MD
University of Chicago Medicine

SESSION 1: TIL AND TRANSGENIC TCR-BASED THERAPIES

8:40 am **Introduction to Session**

Moderator: Tyce Kearl, MD, PhD
Medical College of Wisconsin

8:45 am **Anti-Minor Histocompatibility Antigen and Anti-Neoantigen T Cells in Treatment of Cancer**
Warren Shlomchik, MD
University of Pittsburgh

9:15 am **Personalized TCR-engineered Therapies for Head and Neck Cancer**
Joseph Zenga, MD
Medical College of Wisconsin

JANET ROWLEY LECTURE

9:45 am **Presentation of Janet Rowley Award**
John DiPersio, MD, PhD
WashU Medicine

9:50 am **Janet Rowley Lecture: CAR-T Cell Therapy for Acute Myeloid Leukemia**
Saar Gill, MBBS, PhD
University of Pennsylvania

10:30 am **BREAK**

SESSION 2: UNDERSTANDING COMPLICATIONS OF CELLULAR THERAPY

10:50 am **Introduction to Session**

Moderator: Armin Ghobadi, MD
WashU Medicine

10:55 am **Cytokine Release Syndrome following Chimeric Antigen Receptor T Cell Therapy: Mechanism and Mitigation**
Michael Slade, MD
WashU Medicine

11:25 am **CAR-T Cells and the Brain**
Juliane Gust, MD, PhD
Seattle Children's/
University of Washington

11:55 am **LUNCH**

JONAS MEMORIAL LECTURE

1:00 pm **Presentation of Jonas Memorial Award**
Michael Bishop, MD
University of Chicago Medicine

1:05 pm **CARs and Armored CARs: T Cells for Cancer Therapy**
Renier Brentjens, MD, PhD
Roswell Park Comprehensive Cancer Center

SESSION 3: NOVEL CELLULAR THERAPIES-FROM BENCH TO BEDSIDE

1:45 pm **Introduction to Session**

Moderator: Nirav Shah, MD, MS
Medical College of Wisconsin

1:50 pm **BAFF-R Targeting CAR T-cells In R/R B-cell NHL**
Elizabeth Budde, MD, PhD
City of Hope

2:20 pm **Improving Specificity and Reducing Exhaustion Using a Prime-and-Kill CAR-T Strategy**
Jennifer Clarke, MD, MPH
University of California San Francisco

2:50 pm **BREAK**

SESSION 4: CELLULAR AND GENE THERAPY FOR CLASSICAL HEMATOLOGY: PROGRESS AND CHALLENGES AHEAD

3:10 pm **Introduction to Session**

Moderator: Justin Kline, MD
University of Chicago Medicine

3:15 pm **Gene Therapy for Sickle Cell Disease**
Mitchell Weiss, MD, PhD
St. Jude Children's Research Hospital

3:45 pm **What is the Current Clinical Utility of Gene Therapy for Sickle Cell Disease**
James LaBelle, MD, PhD
University of Chicago Medicine

4:15 pm **High Stakes: Why Being a FINANCIAL Center of Excellence is Critical to Program Success**
Stephanie Farnia, MPH
Nimitt Consulting

4:45 pm **CLOSING REMARKS**
Peter Riedell, MD
University of Chicago Medicine

4:50 pm **ADJOURN**

JONAS CENTER CELLULAR THERAPY SATELLITE SYMPOSIUM FOR RESEARCH TRAINEES

- Half-day research symposium geared towards research trainees and fellows
- Delve into the latest advancements, trends, and challenges shaping the field of cellular therapy
- All trainees are encouraged to submit an abstract describing their original basic science or translational cellular therapy research
- Abstracts will be chosen for either oral or poster presentation

THURSDAY, SEPTEMBER 25 | 12 - 5pm

For more information or to register, visit:
www.JonasCenterSymposium.com

Not open to industry participants.